设为首页 |  加入收藏
首页期刊介绍编委会投稿须知通知公告刊登文章继续教育园地协办单位联系我们广告合作
公告栏:
用NONMEM 法建立癫痫患者丙戊酸群体药代动力学模型
作者:王化明1  萍2  娟3 
单位:1. 暨南大学医学院第三附属医院珠海市人民医院药剂科,广东珠海519000;2. 内江市第二人民医院药剂科,四川内江641000;3. 贵州省人民医院药剂科,贵州贵阳550002
关键词:丙戊酸 群体药代动力学 CYP2A6  癫痫 
中图分类号:R965
文献标志码:A
出版年,卷(期):页码:2012,22(1):1-6,
收稿日期:2011 -11 -20
摘要:
目的建立丙戊酸(VPA)在癫痫患者中的群体药代动力学(PPK)模型,考察固定效应因素对VPA 清除率(CL / F)的影响。方法回顾性收集贵州省人民医院111 名癫痫患者VPA 稳态血药浓度数据及相应的人口学、合并用药及CYP2A6 基因型等资料,随机将患者分成建模组(74 名)及验证组(37 名),使用建模组数据通过非线性混合效应模型(NONMEM)程序建立VPA 的PPK 模型。使用验证组数据来验证模型的准确度和精密度,比较基础模型和最终模型的平均预测误差(MPE)、平均绝对误差(MAE)、平均根方差(RMSE)。结果建立的最终模型包含了日用药剂量(DDO)及CYP2A6 基因型,模型方程为:CL / F = 0. 363·DDO0. 525 ·1.29GENECYP2A6 。最终模型有更好的精密度及准确度,基础模型MPE、MAE、RMSE 值为-10. 63、14. 40、22. 55,最终模型相应值为- 6. 11、9.06、14. 17。结论本研究初步建立癫痫患者VPA 的PPK 模型,VPA 清除率随日给药剂量的增大而增大,CYP2A6 野生型(CYP2A6*1 / *1)组患者较CYP2A6 突变型(CYP2A6*1 / *4、CYP2A6*4 / *4)组患者有更高的VPA 清除率。
To establish valproate ( VPA) population pharmacokinetic( PPK) model in epilepsy patients and study the effect of fixed effect factors on VPA clearance( CL / F). Methods A total of 111 epileptic patients VPA steady-state serum concentration data and the corresponding demography, combination drugs and CYP2A6 gene polymorphism were retrospectively collected at Guizhou Provincial People’s Hospital. The patients were randomly divided into PPK-model group ( n = 74) and PPK-valid group ( n = 37). Population pharmacokinetic model of VPA was established by NONMEM (Nonlinear mixed-effect model) program with PPK-model group data. To assess the accuracy and precision of the basic models and the final model with PPK-valid group data, the average prediction error (MPE), average absolute error ( MAE), and average root variance ( RMSE) were calculated. These values were compared.Results The final population pharmacokinetic model of VPA in epileptic patients included daily does ( DDO) and CYP2A6 gene polymorphism. The regression was CL / F = 0. 363·DDO0. 525 ·1. 29GENECYP2A6 The final model had better precision and accuracy than the basic model, and the values of the basic model MPE, MAE, RMSE were 10. 63, 14. 40, 22. 55, and the values of the final model were -6. 11, 9. 06, 14. 17, respectively. Conclusion This study preliminary established PPK model of VPA in epileptic patients. The clearance rate increases with the daily dose. Compared with CYP2A6 mutations( CYP2A6* 1 / * 4, CYP2A6* 4 / * 4 ), CYP2A6 wild-type ( CYP2A6* 1 / * 1 ) patients have higher clearance rate.
基金项目:
广东省医院药学研究基金(编号:2011A22); 贵州省自然科学基金(黔科合J 字[2006]2058 号)
作者简介:
王化明,药师,Tel:0756 -2162032 Email:wanghuaming2001@163. com
通讯作者:谢 娟,主任药师,Tel:0851 -5923180;Email:xiejuan945@ sohu. com
参考文献:
[1] 于洁, 邵宏, 聂小燕,等. CYP2C19 基因多态性对癫痫患者丙戊酸血药浓度的影响[J]. 中国临床药理学与治疗学, 2007, 12(6): 700 -704.
[2] 白向荣, 姜德春, 王育琴, 等. 中国人群癫痫患者CYP2C19、CYP2C9 的基因型对丙戊酸清除率影响的研究[J]. 中国临床药理学与治疗学, 2007(12).
[3] Tan L, Yu JT, Sun YP,et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients[J]. Clin Neurol Neurosurg, 2010, 112(4): 320 -323.
[4] Jiang D, Bai X, Zhang Q,et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproicacid in Chinese epileptic patients: nonlinear mixed-effect modeling[J]. Eur J Clin Pharmacol, 2009, 65(12): 1187-1193.
[5] Oscarson M, McLellan RA, Gullsten H,et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population[J]. Febs Lett, 1999, 448(1): 105 -110.
[6] Tamaki Y, Arai T, Sugimura H,et al. Association between Cancer Risk and Drug-metabolizing Enzyme Gene(CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) Polymorphisms in Cases of Lung Cancer in Japan[J]. Drug Metab Pharmacokinet, 2011, 26(5): 516 -522.
[7] Schobben F, van der Kleijn E, Gabreels FJ. Pharmacokinetics of di-npropylacetate in epileptic patients[J]. Eur J Clin Pharmacol, 1975, 8(2): 97 -105.
[8] 姜德春, 王丽, 卢炜. 用NONMEM 法建立中国癫痫儿童丙戊酸钠的群体药动学模型[J]. 中国药学杂志, 2007,42(4): 291 -294.
[9] Serrano BB, Garcia SM, Otero MJ,et al. Valproate population pharmacokinetics in children[J]. J Clin Pharm Ther,1999, 24(1): 73 -80.
[10] Yukawa E, To H, Ohdo S,et al. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics[J]. J Clin Pharmacol, 1997, 37(12): 1160 -1167.
[11] EL DE, Fuseau E, EL DAS,et al. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients[J]. Eur J Clin Pharmacol, 2004, 59(11): 783 -790.
[12] Tan L, Yu JT, Sun YP,et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. [J]. Clin Neurol Neurosurg, 2010.
[13] Kiang TK, Ho PC, Anari MR, et al. Contribution of
CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the
CYP2C9*1/ *1 genotype [J]. Toxicol Sci, 2006, 94(2): 261 -271.
[14] Nunoya K, Yokoi T, Kimura K,et al. A new deleted allele in the human cytochrome P450 2A6 ( CYP2A6) gene found in individuals showing poor metabolic capacity to
coumarin and ( + )-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) [J]. Pharmacogenetics, 1998, 8(3): 239 -249.
[15] 胡敏, 张静华, 孙鹤,等. 丙戊酸群体药动学模型的建立与临床应用[J]. 中国医院用药评价与分析, 2001, (2).
[16] 焦正, 钟明康, 施孝金,等. NONMEM 法考察中国癫痫患者丙戊酸和卡马西平的药动学相互作用[J]. 中国药学杂志, 2004, 39(2): 130 -132.
[17] 郁莉斐, 丁俊杰, 石珩,等. 中国癫痫患儿丙戊酸群体药动学模型的建立[J]. 中国循证儿科杂志, 2009, 4(6): 509 -513.
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
 
友情链接  
广东今日药学杂志社有限公司   地址:广州市东风东路753号东塔7楼702
电话:020-37886325       邮箱:jinriyaoxue@163.com
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
粤ICP备20054928号

粤公网安备 44010402002138号

您是第 165217 位访问者